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ABSTRACT 
 
Targeting the metabolism of cancer cells has the potential to lead to major advances in tumor therapy.  Numerous promising 
metabolic drug targets have been identified.  Yet, it has emerged that there is no singular metabolism that defines the oncogenic 
state of the cell. Rather, the metabolism of cancer cells is a function of the requirements of a tumor.  Hence, the tissue of origin, 
the (epi)genetic drivers, aberrant signaling, and the microenvironment all together define these metabolic requirements.  In this 
chapter we discuss in light of (epi)genetic, signaling, and environmental factors the diversity in cancer metabolism based on 
triple-negative and estrogen receptor positive breast cancer, early and late stage prostate cancer, and liver cancer.  These types 
of cancer all display distinct and partially opposing metabolic behaviors (e.g. Warburg versus reverse Warburg metabolism). Yet, 
for each of the cancers their distinct metabolism supports the oncogenic phenotype.  Finally, we will assess the therapeutic 
potential of metabolism based on the concepts of metabolic normalization and metabolic depletion. 
 
INTRODUCTION 
 
Cellular metabolism describes a network of biochemical reactions that convert nutrients taken up from the environment into 
small molecules called metabolites.  These metabolites serve as energy equivalents, redox co-factors, biomass building blocks, 
and substrates for DNA/RNA and protein modifications.  In this way metabolism is involved in virtually any cellular process: E.g. 
proliferation and growth signaling, maintenance of ion gradients across membranes, or epigenetic remodeling via DNA/protein 
modifications.  Hence, metabolism is highly tissue specific, because it is optimized to the function and cellular processes of the 
different organs.  Moreover, metabolism is tightly interconnected with the upstream signaling network to directly link it with the 
regulation of dependent cellular processes. 
 
Cancer cells induce a major reprogramming of essential cellular processes, which leads to novel abilities such as the evasion of 
growth control and cell death, the induction of motility and invasion, and the promotion of angiogenesis and to avoidance of 
immune destruction [1]. Since these processes are directly or indirectly linked to metabolism, the oncogenic transformation of 
cells requires metabolic changes.   Specifically, metabolism fuels the altered cellular requirements of oncogenesis such as energy, 
redox-cofactors, biomass building blocks, or metabolites for DNA/protein modification.  In this sense metabolic changes in 
cancer cells compared to non-malignant cells are a consequence of the cancer needs. Yet, there is also evidence that metabolic 
changes can be a cause of cellular transformation.  It has been shown that the overexpression of certain enzymes such as 3-
phosphoglycerate dehydrogenase leads to oncogenic transformation of non-malignant cells [2]. Also, epidemiological studies 
provide evidence that certain metabolic preconditions such as mutations in the enzyme fumarate hydratase, diabetes, or obesity 
are correlated with a significantly increased cancer risk [3-5].   
Thus, targeting the altered metabolism of cancer cells in the context of the connected (epi)genetics, signaling, 
microenvironments, and tumor heterogeneity has the potential to identify novel therapeutic strategies [6-16].  Besides these 
factors, another essential parameter in the successful development of metabolism-based anti-cancer therapies is the organ in 
which the cancer arises. The organ of origin is important, because its tissue is optimized for a different cellular function with 
specific metabolic needs.  Therefore, oncogenic transformation does not lead to one common set of metabolic changes but 
multiple metabolic changes that overlap only partially and inconsistently.   
 
Here, we will review based on the examples of breast, liver, and prostate cancer the metabolic diversity of tumors. 
Subsequently, we will link the organ specific tumor metabolism to causal (epi)genetic and signaling changes. 
 
BREAST CANCER METABOLISM 
 
Breast cancer facts and current treatment 
 
Breast cancer is the leading cause of cancer death in women worldwide [17].  Thereby, 90% of all breast cancer deaths are 
caused by distant metastases to lung, brain, or bone [18, 19].  Up to 30% of all patients diagnosed with early-stage breast cancer 
develop distant metastases and relapse [18].  
Breast tumors are very heterogeneous at the morphological, molecular, and genetic level [20]. With respect to the treatment of 
breast cancer, three main therapeutic classes can be distinguished.  Patients with estrogen receptor positive tumors (which 
include luminal A and B tumors) receive endocrine therapy [21, 22]. Endocrine therapeutics such as tamoxifen block the estrogen 
receptor and prevent estrogen induced growth signaling in the tumor. Patients whose tumors show human epidermal growth 
factor receptor HER2 (also known as ERBB2) amplification receive anti-HER2 therapy. Triple-negative breast cancers (lacking 
expression of estrogen receptor, progesterone receptor and HER2), which include primarily basal-like tumors, are currently 
treated with chemotherapy [21-23].  
 
In this section we will discuss the metabolic features of triple-negative and estrogen receptor positive breast cancers (Figure 1).  
We focus on these two subtypes, because triple-negative breast cancers have been studied most intensively due to the lack of 
specific therapeutic approaches, their prevalence for distant metastasis [18], and their responsibility for overall high mortality 
rates [24].  Estrogen receptor positive (luminal) breast cancer, on the contrary, has led to a lower death incidence rate than 
triple-negative breast cancer and specific treatment strategies exist, but it is the most frequently occurring subtype (about 70% 
of all breast tumors are estrogen receptor positive) [25].  Generally, the metabolism of these two subtypes differs dramatically: 
triple-negative breast cancers mostly display a classical Warburg metabolism, while estrogen receptor positive breast cancers 
are enriched for a reverse Warburg metabolism. This further shows the need to link genetic, molecular, and environmental 
specificities of cancer cells to their metabolic needs, to enable the development of targeted metabolism based therapies. 
 
Triple-negative breast cancer 
 
Many triple-negative breast cancers display a classical Warburg metabolism with high glucose uptake and increased lactate 
secretion even in the presence of oxygen.  In vivo measurements of glucose uptake rates using fluorine-18 fluorodeoxyglucose 
positron emission tomography (FDG-PET) demonstrated that the highly glycolytic phenotype of triple-negative breast cancers is 
not an artifact from cell culture conditions [26-28].  In line with the increased glucose uptake, several studies have shown an 
increased expression of glucose and lactate transporters, as well as lactate dehydrogenase, which interconverts pyruvate and 
lactate [29-32].   
There is also evidence that the glycolytic rate of triple-negative breast cancers correlates with tumor aggressiveness. A 
retrospective analysis of the Ki-67 nuclear stain, which is a measure for the proliferation index of tumors, with the maximal 
glucose uptake rates measured by FDG-PET showed a strong correlation of both parameters in triple-negative breast cancers 
[26]. In line with this finding a correlation between the expression of monocarboxylate transporter 4 (needed for lactate 
secretion) and clinical outcome has been discovered [29].  Interestingly, while lactate dehydrogenase A is ubiquitously highly 
expressed in many breast tumors, it has been shown that lactate dehydrogenase B is essential for triple-negative breast cancers 
and co-expressed with monocarboxylate transporter 1 [32].  This is surprising, since lactate dehydrogenase B is believed to 
preferentially convert lactate to pyruvate [33, 34].  Yet, another study showed that the knockdown of lactate dehydrogenase B 
similar to the knockdown of lactate dehydrogenase A increased oxygen consumption [35], which is unexpected since these 
enzymes preferentially use either pyruvate or lactate as a substrate. Thus, the metabolic role of lactate dehydrogenase B in 
triple-negative breast cancer remains to be elucidated. 
 
The glycolytic phenotype of triple-negative breast cancer correlates with the proliferation index.  This implies that glycolysis is 
important to fuel the energy, redox, or biosynthetic needs of fast growing tumors.  Yet, it is currently not clear which of the three 
metabolic needs is most important for triple-negative breast cancers.  Interestingly, activation of oxidative metabolism in triple-
negative breast cancers led to decreased metastasis and decreased tumor growth [36]. This activation was triggered by 
increasing the activity of complex I of the respiratory chain, which results in an increased NAD+/NADH ratio [36, 37]. Santidrian et 
al. correlated the increased NAD+/NADH ratio with decreased mTORC1 activity [36] and subsequently increased autophagy [36]. 
These data argue for a small dynamic range of redox metabolism in triple-negative breast cancer, implying that any imbalance 
between reduced and oxidized redox cofactors might hamper tumor growth and that only the combination of decreased 
oxidative phosphorylation with increased glycolysis allows fast proliferation in certain types of triple-negative breast cancers. 
 
Triple-negative breast cancers have been shown to display an increased uptake of glutamine and cholesterol, while the de novo 
synthesis of these metabolites was decreased [38-40].  Timmerman et al. demonstrated in a subset of breast cancer cells -which 
was highly enriched for the triple-negative subtype- that targeting the activity of the xCT glutamate-cystine antiporter (which 
mediates the exchange of extracellular L-cysteine and intracellular L-glutamate across the cellular plasma membrane) reduced 
tumor growth in vivo and in vitro [39]. Recent studies also found that estrogen receptor negative breast cancers (which include 
triple-negative breast cancers) have a low glutamine synthetase activity [40], resulting in a significantly increased glutamate-to-
glutamine ratios compared to normal tissue [41].  Contrary to triple-negative breast cancer, estrogen receptor positive breast 
cancers have a high glutamine synthetase activity and increased glutamine secretion [40]. Furthermore, cholesterol storage in 
the form of cholesterol esters produced by acyl-CoA:cholesterol acyltransferase and cholesterol trafficking was increased in 
triple-negative breast cancer [38].  
 
In contrast to the decreased de novo synthesis of glutamine and cholesterol, many triple-negative breast cancers activate the 
serine-glycine biosynthesis pathway. This is mainly caused by gene amplification or expression increase in the enzymes of the 
serine-glycine pathway such as 3-phosphoglycerate dehydrogenase [42-44].  Interestingly, in non-transformed breast cancer cell 
lines 3-phosphoglycerate dehydrogenase is rate limiting for serine biosynthesis [42].  This is opposite to the liver where it has 
been found that phosphoserine phosphatase is rate limiting [45].  This difference could be explained by low intra cellular serine 
levels in the breast compared to the liver and thus full activity of phosphoserine phosphatase (which is feedback-inhibited by 
serine) [42].  Corroborating the relevance of alterations in the serine pathway, increased expression of 3-phosphoglycerate 
dehydrogenase and phosphoserine aminotransferase 1 are correlated with a decreased relapse-free time and reduced overall 
survival of breast cancer patients [44].  Moreover, the overexpression of 3-phosphoglycerate dehydrogenase, phosphoserine 
aminotransferase 1, serine hydroxymethyltransferase, or glycine dehydrogenase provoked an oncogenic transformation of non-
malignant cells in vitro [43, 46, 47].  
Currently, it is not well understood how alterations in serine-glycine metabolism support tumor proliferation.  On one hand, 
serine hydroxymethyltransferase, and glycine dehydrogenase both provide 5,10-methylene-THF, which is an important cofactor-
precursor for nucleotide biosynthesis and DNA methylation; and both processes are increased in many tumors [2, 48].  
Moreover, the first chemotherapeutic agents (which are chemical derivatives are still used today) were anti-folates and inhibit 
enzymes in the folate pathway, such as dihydrofolate reductase [49]. Dihydrofolate reductase provides THF, which is a precursor 
to 5,10-methylene-THF.  On the other hand, the proliferation defect induced by the knockdown of amplified 3-phosphoglycerate 
dehydrogenase in triple-negative breast cancers could not be rescued with the supplementation of extracellular serine [42, 43], 
despite the fact that extracellular serine can fuel folate metabolism [50]. Thus, increased supply of serine does not seem to be 
the critical function of 3-phosphglycerate dehydrogenase amplification.  Interestingly, Possemato et al. suggested that the 
coupling of serine biosynthesis to α-ketoglutarate production could be important in 3-phosphglycerate dehydrogenase amplified 
cells [42].  Thus, multiple roles of serine-glycine metabolism for breast cancer proliferation are possible, and the identification of 
precise mechanisms requires further study. 
In contrast to the success of an anti-folate therapy, several epidemiological studies showed that the risk of breast cancers (and 
maybe particularly estrogen receptor-negative breast cancer [51]) is reduced with increased dietary levels of folate [51-56].  This 
controversial finding of intracellular serine-glycine-folate metabolism versus extracellular, nutrient-derived folate clearly 
demonstrates the need to not only identify metabolic differences in diseased versus healthy cells, but also to understand the 
regulation of metabolism based on nutrient availability.  This important link between nutrient availability and intracellular 
metabolism is further highlighted through epidemiological studies that associate obesity with the prevalence of triple-negative 
breast cancer [57]. 
 
Estrogen receptor positive breast cancer 
 
In contrast to triple-negative breast cancers, many estrogen receptor positive breast cancers display the so-called reverse 
Warburg effect.  The reverse Warburg effect in estrogen receptor positive breast cancers includes the metabolic interaction 
between tumor cells and stromal cells. Thereby, cancer cells promote the metabolic reprogramming of stromal cells such as 
fibroblasts into cancer-associated fibroblasts [58]. Specifically, fibroblasts co-cultured with breast cancer cells displayed 
decreased caveolin 1 expression, and induction of HIF1D and NFNB [59]. Notably, HIF1D stabilization can lead to aerobic 
glycolysis and subsequent increase in lactate and pyruvate secretion via the overexpression of the monocarboxylate transporter 
4 [60].  In turn, the cancer cells use the secreted lactate and pyruvate to fuel their tricarboxylic acid cycle [60].  Thus, in this 
complex interaction, the cancer-associated fibroblasts display a glycolytic metabolism, while the cancer cells rely on oxidative 
metabolism. The in vivo occurrence of Warburg versus reverse Warburg effect was shown based on immunostaining of several 
indicative proteins such as glucose transporter 1, monocarboxylate transporter 4, and ATP synthase in tumoral and stromal 
tissue microsections [30].  Interestingly, this symbiotic behavior of lactate catabolizing and anabolizing cells does not only exist 
between tumor cells and cancer-associated fibroblasts, but also between tumor cells residing in hypoxic regions and tumor cells 
residing in oxygenated regions [61]. 
 
In conclusion, triple-negative and estrogen receptor positive breast cancers show very diverse metabolic phenotypes  with 
rapidly proliferating triple-negative breast cancers displaying a pronounced glycolytic phenotype.  This raises the question 
whether fast proliferation requires a glycolytic metabolism? In line with this notion is the fact that luminal B estrogen receptor 
positive breast cancers, which are defined by a high proliferative index, display less often a reverse Warburg metabolism 
compared to slow proliferating luminal A estrogen receptor positive breast cancers [30]. Thus, a glycolytic metabolism might 
promote fast proliferation, yet we still need to understand which metabolic requirement it fulfills. 
 
Genetic alterations in breast cancer and their connection to metabolism  
 
In addition to the proliferative index of tumors, genetic alterations define metabolic needs of breast cancer cells. The most 
commonly mutated gene in breast cancer is p53 [62]. P53 is a major regulator of apoptosis, senescence, and cell cycle arrest. 
However, p53 also regulates various enzymes in metabolism and can promote an oxidative metabolism over a glycolytic 
metabolism [63].  Yet, there is also evidence that certain metabolic targets of p53 such as hexokinase rather promote than 
inhibit glycolysis [63]. Thus, alterations in p53 status might be able to contribute to both, the Warburg metabolism of triple-
negative breast cancer and the reverse Warburg metabolism of estrogen receptor positive breast cancer. 
The oncogene MYC is a major regulator of glutamine and glucose metabolism [64].  Specifically, MYC promotes catabolism of 
glutamine (for instance, through glutaminase 1 regulation) [65].  Since many triple-negative breast cancers have elevated MYC 
expression [66], this could explain their shift from glutamine synthesis to glutamine uptake.  Additionally, MYC induces glycolysis 
by up-regulating lactate dehydrogenase [65] and glucose uptake [67].  Yet, glucose metabolism is not only under the control of 
MYC and p53.  Alvarez et al. demonstrated the importance of the genetic drivers by determining glucose uptake in breast cancer 
tumors by FDG-PET. Specifically, Akt- and MYC- driven tumors exhibited higher FDG uptake than Wnt1-, HER2-, or RAS- driven 
tumors, although without a difference in tumor growth. At molecular level, FDG uptake and the activity of the above-mentioned 
pathways was generally associated with hexokinase-2 and HIF-1α stabilization, whereas an association with glucose transporter 
1 was only observed in Akt- and HER2-driven tumors [67]. 
Additionally, the amplification/overexpression of the genetic driver HER2 defines fatty acid metabolism in one subtype of breast 
cancers: It has recently been suggested that HER2 directly phosphorylates and thereby activates fatty acid synthase [68].  Thus, 
fatty acid synthase inhibitors might be potent drugs in HER2 amplified breast tumors [68].  
 
LIVER CANCER METABOLISM 
 
Liver cancer facts and current treatment 
 
Under normal physiological conditions the liver performs essential functions such as processing nutrients, degradation and 
storage of body fuels and clearance of toxins.  To fulfill these functions, hepatocytes are highly specialized and organized in 
periportal or perivenous hepatocytes, this is known as functional zonation. Mostly affected by this zonation are processes like 
ammonia detoxification, glucose/energy metabolism and xenobiotic metabolism.  
Hepatocellular carcinoma (HCC) is one of the deadliest and most common cancers worldwide [69]. In the development of HCC, 
nutrition and metabolic related factors like alcohol consumption, aflatoxin contamination in food [70], the gut microbiota [71], 
diabetes [72] and bodyweight [73] influence initiation and progression of HCC. To treat HCC is difficult, because its onset often 
occurs on top of an underlying liver disease such as hepatitis B or C virus infection, alcoholic liver disease, or non-alcoholic fatty 
liver disease. Depending on the stage of the cancer and the liver function, surgical resection, liver transplantation and 
radiofrequency ablation are options for patients with early stage disease. For advanced liver cancer the multi-kinase inhibitor 
Sorafenib is to-date the only approved agent [69, 74]. In the following sections, we focus on the metabolic features of healthy 
versus cancerous liver tissue and the connected (epi)genetic and signaling drivers (Figure 2).  
 
Metabolic alterations in liver cancer 
 
The most fundamental change in HCC metabolism is the switch from glucose production (gluconeogenesis) to glucose usage. For 
more than 50 years it has been described that in liver cancer compared to normal liver cells the activity of glucose-6-
phosphatase, phosphoenolpyruvat-carboxykinase, as well as fructose-diphosphatase and hence gluconeogenesis is decreased or 
absent [75-79]. Ma et al. showed in 2013 that this lack of gluconeogenesis might occur due to the decreased expression of 11β-
hydroxysteroid dehydrogenase type 1 and an increased expression of 11β-hydroxysteroid dehydrogenase type 2. These enzymes 
control the activity of glucocorticoids [80]. Glucocorticoids promote gluconeogenesis, but in liver cancer cells the altered 
expression of 11β-hydroxysteroid dehydrogenase1/2 results in the insensitiveness of liver cancer cells to endogenous 
glucocorticoids [81]. Moreover, it was shown that Stat3-mediated activation of the microRNA23a suppresses gluconeogenesis by 
targeting glucose-6-phosphatase expression [79]. Consistently, restoring gluconeogenesis by dexamethasone treatment showed 
significant inhibition of in vivo tumor growth [80]. A block in gluconeogenesis might contribute to the survival of HCC cells by 
increased usage of glycolysis and pentose phosphate pathway due to accumulation of glucose-6-phosphate [79]. In addition to 
the fundamental loss of gluconeogenesis, it was demonstrated that glycogenesis also decreases during the oncogenic 
transformation of liver [75, 78, 82]. Both phenomena indicate that the catabolism of glucose, compared to its anabolism and 
storage in the form of glycogen, is essential for liver cancers. 
 
Further evidence for the importance of glucose catabolism in liver cancer has been described since the sixties. Rapid 
proliferation was correlated with increased activity of fetal-type liver enzymes like hexokinase 2, glucose-6-phosphate 
dehydrogenase and pyruvate kinase-M2 [78]. In accordance a decreased activity for adult-type liver enzymes like hexokinase 4, 
or pyruvate kinase-L was measured[83]. To enable a high glycolytic capacity, the liver cancer tissue must attain an enhanced 
uptake of glucose. While glucose transporter 2 is most important in healthy liver, the fetal glucose transporter 1 is upregulated in 
HCC, and its expression is correlated with HCC proliferation and invasiveness [84-87]. Moreover, patients with a high glucose 
transporter 1 expression showed higher α-fetoprotein (HCC tumor marker) and poorer differentiation compared to the glucose 
transporter 1 low-expression cohort [88]. Finally, FDG-PET imaging confirmed that the described alteration in the expression of 
glycolytic enzymes and glucose transporter results in an increased glucose uptake rate [88-90].  
 
Besides glucose metabolism, glutamine metabolism is also significantly altered in liver cancer. The liver-type glutaminase 2, 
which catalyzes the conversion of glutamine to glutamate is almost absent or significantly decreased in human HCC [91]. 
Consistently, the expression of glutamine synthetase, which catalyzes the opposite reaction, is increased in HCC patients with β-
catenin mutations [92-94]. Glutamine synthetase is a target gene of β-catenin and overexpression of glutamine synthetase is 
highly correlated with β-catenin mutations [92], which in turn is related to early-stage HCC [95]. Moreover, glutamine synthetase 
expression is correlated with HCC progression [93, 96]. Supporting the importance of glutamine metabolism in liver cancer, 
increased concentrations of glutamate and glutamine have been detected in human HCC in comparison to adjacent normal 
tissue [97].  Interestingly, glutamine synthethase expression is related to liver regeneration and therefore is observed during 
cirrhosis (a pre-state of liver cancer) [93, 98].  Thus, whether glutamine synthetase expression is a drug target or only a 
biomarker remains to be determined. 
 
Differential lipid metabolism is an important risk factor in liver cancer [99-101]. Accordingly, the expression of stearoyl-CoA 
desaturase, a membrane protein of the endoplasmic reticulum that catalyzes the formation of monounsaturated fatty acids from 
saturated fatty acids, was found to be associated with aggressiveness of HCC [100-102].  Moreover, suppression of stearoyl-CoA 
desaturase could reduce proliferation in HCC cell lines in an Akt-dependent fashion [100]. One proposed mechanism for the 
correlation between stearoyl-CoA desaturase expression and HCC aggressiveness might be the systemic link to insulin signaling. 
Specifically, monounsaturated fatty acids could have an insulin-sensitizing function and thus affect glucose uptake, leading to 
enhanced capacity for cell proliferation [103]. In addition to desaturation of lipids, also de novo lipid synthesis was increased in 
liver cancer. Calvisi et al showed a progressive induction of mRNA and protein expression of fatty acid synthase, adenosine 
triphosphate citrate lyase, acetyl-CoA carboxylase, malic enzyme, stearoyl-CoA desaturase 1, 3-hydroxy 3-methylglutaryl-CoA-
reductase, mevalonate kinase, and squalene synthetase, sterol regulatory element-binding protein 1 and 2, liver X receptors α  
and  β, and carbohydrate responsive element binding protein. The induction of these enzymes was most pronounced in a patient 
cohort with poor survival outcome [100].  
 
In conclusion, the loss of gluconeogenesis and potentially glycogenesis is a major factor in the metabolic reprogramming of 
transformed liver cells. Consequently, glycolysis and fatty acid synthesis are activated. This major switch implies that re-
activation of gluconeogenesis has the potential to counteract liver cancer progression (see therapy section). Moreover, it is 
striking that many of the embryonic isoforms of enzymes such as hexokinase 2 are activated, while the adult isoforms are 
downregulated. This implies that the liver cancer cells use the embedded natural processes of embryonic proliferation to sustain 
their uncontrolled proliferation phenotype. 
 
Genetic, epigenetic, and signaling drivers of Liver Cancer and their connection to metabolism  
 
The most frequently mutated genes in liver cancer are p53 and E-catenin [104]. Also signaling pathways like EGFR, VEGFR, Met 
and intracellular mediators such as Ras and Akt/mTORC1 may play a role in HCC development and progression [104, 105]. With 
no common mutations in coding genes that can account for all cases of HCC, it is likely that epigenetic changes are key driving 
mechanisms of HCC development [106]. In line with this, aberrant DNA methylation patterns have been reported [107] and also 
histone deacetylase 2 is commonly upregulated in human HCC [108]. In this section we discuss how these genetic drivers are 
linked to metabolic changes in liver cancer.  
 
The p53 status in liver cancer can contribute to the alterations in glucose and glutamine metabolism. Huang et al. identified 
CD147 as an important regulator of the Warburg metabolism in HCC cells via a p53 route [109]. Additionally, Hu et al. 
demonstrated that the down-regulation of glutaminase 2 is p53-dependent. Thus, the p53 status of liver cancer may contribute 
to the altered glucose and glutamine metabolism during oncogenesis [91]. Another enzyme involved in glutamine metabolism is 
the β-catenin target gene glutamine synthetase. Overexpression of glutamine synthetase is highly correlated with β-catenin 
mutation [92].  
Mutant EGFR has been shown in other cancer types to activate Stat3 pathway by means of IL-6 upregulation [110]. This 
contributes to inhibition of gluconeogenesis through Stat3-mediated, glucose-6-phosphatase suppression in HCC [79]. 
  
Histone deacetylase 2 is commonly upregulated in HCC. Upon histone deacetylase 2 knockdown, glycolysis and lipid 
accumulation are decreased due to the inhibition of PPARJChREBPα, FAS and SREBP regulation [108].  Additionally, the 
knockdown of histone deacetylase 2 increased acetylation of p53 and in turn led to the expression of p53 target genes, which 
can counteract the metabolic requirements of liver cancer cells.   
 
PROSTATE CANCER 
 
Prostate cancer facts and current treatment 
 
Prostate cancer is the most commonly diagnosed cancer in men in developed countries [17].  Whereas patients with well 
differentiated tumors can mostly be cured (9.1 % mortality after 10 years [111]), the outcome for patients with progressed and 
poorly differentiated tumors is detrimental (25.6% mortality after 10 years [111]).  
Currently, there are several options to treat prostate cancer depending on its progression. At first, these therapies include 
androgen deprivation therapy, radical prostatectomy and different radiation therapies [112-114]. Advanced, relapsing and 
castration-insensitive prostate cancers are largely treated with therapies that target the androgen signaling pathway and 
immune therapy (reviewed in [115, 116]). In addition, more attempts to develop drugs that act on other prostate cancer targets, 
such as ETS-fusions, or the PI3K signaling pathway, or fatty acid metabolism, are reported [117, 118]. 
Prostate cancer originates in the peripheral zone of the prostate where about 70% of the cancer emerges in a multifocal manner 
[119]. Upon an inflammatory event, reactive oxygen species accumulation and certain driver mutations, normal epithelial cells 
progress through different stages to build an adenocarcinoma. These stages start with the build-up of prostatic intra-epithelial 
neoplasia, which then develops into an adenocarcinoma. The latter might become castration-insensitive and metastasizes, 
preferentially in bone (reviewed in [119]). 
Initiation and progression of prostate cancer are highly coupled with metabolic rearrangements.  In the following we divide 
these metabolic events into early changes (primary tumor-metabolism) and late stages (undifferentiated and castration-resistant 
prostate cancer metabolism) (Figure 3).  
 
Early stage prostate cancer metabolism 
 
In contrast to other tissues, normal prostate epithelial cells rely on aerobic glycolysis, because the tricarboxylic acid cycle enzyme 
m-aconitase (and thus glucose oxidation) is blocked by high intracellular zinc levels (i.e. zinc levels three to 10-fold higher than in 
other soft tissues [120-122]). As a consequence, citrate accumulates and is excreted into the prostatic fluid. In an early step 
during the transition from healthy to malignant tissue, prostate cells lose their ability to accumulate zinc due to the down-
regulation of zinc transporters (mainly ZIP1) [122, 123]. Therefore, the block of the tricarboxylic acid cycle is relieved and the 
cells switch their metabolism to generate energy via oxidation of citrate and coupled respiration. Concomitant low glucose 
uptake rates (i.e. FDG-PET cannot be used to detect primary tumors; reviewed in [124, 125]) suggest that other substrates are 
fueling cancer growth. Specifically, a lactate-shuttle between cancer-associated fibroblasts and tumor-tissue was proposed [126], 
since cancer-associated fibroblasts express the monocarboxylate transporter 4 and tumors overexpress the monocarboxylate 
transporter 1 (reverse Warburg effect) [127-130]. This relationship allows the tumor to take up lactate and to convert it to 
pyruvate, which is processed in the tricarboxylic acid cycle. However, opposing this model, prostate tumors overexpress lactate 
dehydrogenase A [129, 131-133], which preferentially works in the direction of lactate production [33, 34]. Consistently, lactate 
dehydrogenase B, which catalyzes the lactate to pyruvate conversion, is suppressed [131, 134]. This is further functionally 
supported by experiments with hyperpolarized pyruvate, where in situ tumors convert pyruvate into lactate [135-137]. Thus, it is 
questionable whether cells in vivo exchange lactate or rather other substrates (e.g. pyruvate, since the Km of monocarboxylate 
transporter 1 for pyruvate is lower than for lactate [126]). Specifically, a more systematic analysis of the cancer environment and 
consumption and secretion rates might be helpful in resolving this inter-cell-dependency.  
However, the cell-cell interaction seems to support in any case oxidative phosphorylation, which is in line with a reverse 
Warburg metabolism. In addition, prostate cancer cells seem to induce peroxisomal branched-chain fatty acid oxidation (alpha-
methylacyl-CoA racemase, D-bifunctional protein, acyl-CoA oxidase 3), which includes α-oxidation and a partial β-oxidation [129, 
138-142]. Moreover, the short chain fatty acids, which then are released from the peroxisome might further fuel the TCA cycle 
by their full β-oxidation in the mitochondria. Although enzymes of mitochondrial β-oxidation are not increased in prostate 
cancer [140], it has been shown that etomoxir-mediated inhibition of mitochondrial β-oxidation at the level of carnitine 
palmitoyltransferase 1 induces cell death in prostate cancer cell lines [143]. Interestingly, prostate cancer also induces fatty acid 
biosynthesis by overexpressing fatty acid synthase early during tumor progression without lipid accumulation [144, 145], which 
is further consistent with 11C-acetate PET/CT experiments [146]. Why a futile cycle of simultaneous fatty acid oxidation and fatty 
acid synthesis is beneficial to prostate cancer cells remains an open question. 
 
Later stage prostate cancer metabolism 
 
Further dedifferentiation of the tumor is connected with a more pronounced expression of monocarboxylase transporter 1, 
lactate dehydrogenase A, altered cholesterol metabolism [147], as well as with a boost in fatty acid biosynthesis and associated 
enzymes (reviewed in [118]). Moreover, inhibition of fatty acid biosynthesis and oxidation was reported to inhibit tumor growth 
[143, 148, 149]. Yet, cancer cell lines, such as DU-145, LNCaP and PC-3 exhibit an elevated fatty acid uptake from the 
environment, which renders them less sensitive to inhibition of fatty acid biosynthesis [150-152]. This further underlines the 
importance of considering the microenvironment, which potentially modulates intracellular metabolism [152]. Additionally, high 
grade (Gleason > 7) and castration-resistant tumors seem to reactivate glycolysis, since FDG-PET and FDG-PET/CT studies 
indicate an increased glucose uptake compared to benign and low stage prostate cancers [153-157]. Accordingly, prostate cancer 
is affected by 2-deoxyglucose [158-160].  This is further in agreement with cell line studies, which show that the metastastic 
androgen-sensitive cell line LNCaP and the castration-resistant low-differentiation cell lines DU-145 and PC-3 are sensitive to 
glucose starvation [152] and that androgen signaling enhances the expression of glycolytic enzymes [161-163]. However, 
whether or not an increased expression of the glucose transporter 1 or other hexose transporters are causal for this phenotype 
is still a matter of debate, since histological data are inconclusive [164-167]. 
 
Interestingly, it was shown in vitro and in xenograft models that prostate cancer cell lines are highly dependent on the 
phosphofructokinase-fructose-bisphosphatase 2 isoform PFKFB4 and on glucose-6-phosphate dehydrogenase [152, 168]. 
Specifically, PFKFB4 drives the balance of glucose-6-phosphate and fructose-1,6-bisphosphate towards glucose-6-phosphate. 
Latter is used as a substrate in the glucose-6-phosphate dehydrogenase reaction, the initial step of the oxidative pentose 
phosphate pathway. This suggests that a substantial portion of the glucose taken up is channeled through the pentose 
phosphate pathway for reduction of NADP+ and consequently glutathione disulfide, as well as for de novo nucleotide 
biosynthesis [168, 169]. Besides, prostate cancer still relies on oxidative phosphorylation, which is enforced by the interaction 
with cancer-associated fibroblasts as shown for PC-3 cells [127]. Consistently metformin, an inhibitor of mitochondrial complex I, 
provokes a decrease of proliferation with a subsequent activation of reductive glutamine metabolism in vitro and in a TRAMP 
mouse model [159, 170]. Moreover, a combinatorial therapy of metformin and an inhibitor of glutamine metabolism might be 
promising for therapeutics, since PC-3 and DU-145 cell lines are reportedly glutamine addicted [171, 172], and respiration and 
fatty acid biosynthesis could thus be inhibited simultaneously [170].  
 
In sum, so far published data indicate that the first step of an oncogenic transformation of the prostate is a switch to oxidative 
metabolism. During prostate cancer progression to castrate-resistance this oxidative or reversed Warburg metabolism changes 
to a mixed Warburg metabolism, where both, glycolysis and respiration serve as sites for energy and biomass precursor 
generation.  
 
Genetic drivers, signaling and microenvironment in prostate cancer and their connection to metabolism 
 
In the past decades several drivers for prostate cancer and progression were identified at the genomic, transcriptional and 
protein-level [119, 173-182]. The acquisition of these driver mutations and subsequent tumor progression could either follow a 
linear pathway or a molecular diversity model as suggested by Rubin et al., 2011 [178]. Early drivers are commonly thought to be 
loss of the transcription factor NKX3.1 protein expression, activation of the MYC transcription factor and TMPRSS2-ERG gene-
fusions. These events are often followed by alterations in the PI3K signaling, RB signaling and RAS/Raf signaling, which render the 
tumor more aggressive [176]. Finally, androgen-resistance occurs, which is consistent with the fact that most metastatic tumors 
have an alteration in the androgen signaling pathway [173, 176, 180].  While there was much effort in mechanistically unraveling 
these signaling pathways and their interplay, there is less knowledge about their specific impact on prostate cancer metabolism.  
As mentioned above, a key event in prostate cancer initiation is the down-regulation of zinc-transporters, which then allows the 
cancer to fully oxidize citrate. The regulation of zinc transporters in prostate cancer was shown to depend on the expression of 
the microRNA cluster miR-183-96-182, which correlates with Gleason score [183, 184]. Another mechanism involves the RAS 
responsive element binding protein-1 [185]. Specifically, it was found that RAS responsive element binding protein-1 is 
overexpressed early in prostate carcinogenesis and that it down regulates zinc-transporter 1. Although zinc-transporter 1 might 
be a target for therapy, currently no drug exists to activate this transporter [123]. Additionally, a low zinc level might be 
maintained in later stages by HoxB13-mediated induction of the zinc output transporter ZnT4[186]. 
The progressive switch of reverse Warburg metabolism to a mixed Warburg metabolism is mediated by a multitude of signaling 
pathways, which reportedly include p53 loss, PI3K/AKT activation, MYC overexpression, and androgen signaling. The links to 
metabolism for p53 loss, PI3K/AKT signaling and MYC were investigated with the focus on specific metabolic pathways; i.e. MYC 
induces glutaminase and proline synthesis via miR-23a/b [187, 188], the PI3K/AKT pathway up-regulates FASN expression [189, 
190], and p53 loss induces mitochondrial aconitase expression [191]. The role of the androgen receptor in the induction of a 
mixed Warburg phenotype was more globally assessed. Increased androgen receptor signaling might directly or with the aid of 
other signaling pathways increase overall metabolic activity [161, 162, 167]. Specifically, AMPK and consequently PGC-1α could 
be activated by androgen receptor-dependent CAMKK induction, which is connected to increased glycolysis and lactate 
excretion, but also mitochondrial biogenesis [161, 163]. Increased glycolytic metabolism is further supported by higher 
hexokinase 2 expression, which is at least partly triggered by androgen-receptor-dependent activation of PKA/CREB [162]. 
Interestingly, AMPK activation seems not to antagonize mTOR signaling status [161] and thus allows a mTOR-dependent 
induction of glucose-6-phosphate dehydrogenase and the oxidative pentose phosphate pathway [168], which allow an increased 
NADP+-reduction and nucleotide biosynthesis.  
Besides, hypoxic environments and pseudo-hypoxia might play a pivotal role in the modulation of prostate cancer metabolism 
via  HIF1α   stabilization.   It  was   shown   that  HIF1α  generally   upregulates lactate dehydrogenase A, mitochondrial aconitase, and 
more specifically fatty acid synthase in high grade tumors [192]. Corroborating this result E-arrestin 1 is up-regulated in high 
grade prostate cancer and stabilizes HIF1α, which is connected to a reduction of succinate dehydrogenase A, fumarate 
hydratase, dihydrolipoamide dehydrogenase, dihydrolipoyl transacetylase and pyruvate dehydrogenase [193]. This was further 
accompanied with an up-regulation of glucose uptake and lactate secretion [193]. Overall this indicates that prostate cancer 
might partly promote anaerobic glycolysis and reductive carboxylation from glutamine in a HIF1α-dependent manner. 
In summary, the comparison between breast, liver and prostate cancer clearly shows that the tissue of origin has a substantial 
contribution to the definition of a transformed versus healthy metabolism. For example, the reactivation of respiratory 
metabolism in the prostate is of oncogenic potential while as well the highly glycolytic phenotype of tripe-negative breast 
cancers sustains tumor proliferation. Beyond the tissue of origin it seems equally important to consider the (epi)genetic drivers, 
aberrant signalling and the microenvironment, since different subtypes of tumors from the same tissue result in a differential 
metabolism as described for breast cancer. Moreover, the metabolism within one tumor is not static, but -as highlighted for the 
prostate- it is a dynamic parameter that adapts to the requirements during tumor progression. 
 
THERAPEUTIC OPPORTUNITIES OF CANCER METABOLISM 
 
The central role of metabolism for all cellular processes in the cell defines it as a promising target for cancer therapy (Table 1), 
specifically because catalytic functions of metabolic enzymes are generally considered to be easily druggable by small molecules 
[15]. Metabolism is the downstream converging point of the highly interconnected signaling pathways, thus side-effects are less 
likely and resistance mechanisms harder to employ [7]. Moreover, metabolic changes are necessary to enable a certain 
carcinogenic  phenotype.  There are two concepts for metabolic drugs, which are given by normalization and depletion. In the 
concept of normalization, metabolic drugs enforce the redirection of the metabolic fluxes (which are the conversion rates of 
metabolites throughout the metabolic pathways) towards a normal metabolism as defined by healthy cells in the same tissue. In 
the concept of depletion, metabolic drugs inhibit a pathway that is predominantly essential for the tumor cells and thus they 
drain the metabolic requirements of the tumor.  
 
The concept of depletion has a long-standing history in cancer treatment with anti-folates, nucleoside analogues, and 
asparaginase [49, 194, 195] as examples. The underlying principle for the use of anti-folates and nucleoside analogues is the 
dependency of fast proliferating cells on de novo DNA synthesis. Since not only cancer cells can display a fast proliferation, these 
drugs lead to a general collateral damage. Nevertheless, their efficiency and side-effects are similar to other non-metabolic 
chemotherapeutic agents such as paclitaxel, which inhibits mitosis [196, 197]. The expression of asparaginase is a more specific 
therapy than nucleoside analogues, since acute lymphoblastic leukemia are asparagine auxotrophs and depend on the uptake of 
sufficient amounts of asparagine. Thus the expression of asparaginase depletes the availability of asparagine because it degrades 
it to aspartate [194].  
The same concept of depletion applies to more recently found inhibitors of fatty acid synthase or choline kinase [198, 199], 
which are in various (pre)clinical phases.  Thereby, the concept of depletion goes always along with the risk that either the 
metabolites that are synthesized can be taken up from the environment or that the pathway is also essential for non-
tumorigenic cells. 
 
The concept of normalization is built upon the fact that some metabolic pathways such as glycolysis are also needed in healthy 
cells and that cancer cells display a hyperactivation of such pathways. A preclinical example for the former is 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 3, which is a positive regulator of the glycolytic enzyme phosphofructoskinase.  Inhibition of 
this regulator decreases but does not inhibit glycolysis. Thus, normalization is sufficient to lead to proliferation inhibition, while 
healthy cells with lower glycolysis are unaffected [200].  Accordingly, targeting the 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 in hyper-sprouting blood vessels leads to a normalization of the blood vessels [201]. 
Not only the normalization of hyperactivated metabolic pathways leads to a therapeutic benefit, but also the reactivation of 
pathways that are active in healthy tissue. This is exemplified by the potency of reactivating gluconeogenesis in liver and kidney 
cancer. In the healthy liver glucocorticoids promote gluconeogenesis. However, in liver cancer cells, the enzymes that convert 
the glucocorticoids into their active form are aberrantly regulated, resulting in the insensitivity of liver cancer cells to 
endogenous glucocorticoids [202].  Yet, treating liver cancers with dexamethasone, which is a synthetic and active 
glucocorticoid, led to the re-activation of gluconeogenesis and increased therapeutic efficacy [202].  Recently, it was also shown 
that the re-expression of the gluconeogenic enzyme fructose 1,6 bisphosphatase 1 in renal cell carcinoma antagonized its 
glycolytic phenotype [203].  
Examples for novel drug targets, which are in pre-clinical and clinical trials and follow the concept of normalization are inhibitors 
of the mutant form of isocitrate dehydrogenase.  Point mutations in isocitrate dehydrogenase isoform 1 or isoform 2 are highly 
abundant in glioma, glioblastoma, and acute myeloid leukaemia.  The presence of mutant isocitrate dehydrogenase in the cell 
leads to the production of 2-hydroxyglutarate from α-ketoglutarate, which is the product of the non-mutated isocitrate 
dehydrogenase reaction. Since 2-hydroxyglutarate is an endpoint metabolite that is not further converted, it rapidly accumulates 
in the cells and outcompetes the structurally similar α-ketoglutarate as a cofactor for α-ketoglutarate-dependent dioxygenases 
[204, 205].  This leads to an inhibition of the α-ketoglutarate-dependent dioxygenases and consequently to histone 
hypermethylation [206].  The altered methylation patterns thereby promote dedifferentiation of the tumors.  Consequently, the 
specific inhibition of the mutant isocitrate dehydrogenase enzyme normalizes the methylation pattern in the tumor and leads to 
differentiation of tumor cells and inhibition of tumor proliferation [207-209].  Mutant isocitrate dehydrogenase inhibitors 
thereby constitute an ideal case of a drug target, since the mutation is only present in the tumor but not in any healthy tissue 
throughout the body. 
 
In conclusion, metabolism offers a wide range of drug targets that can be exploited for cancer therapy.  Yet, the current 
challenge is to overcome the idea that metabolism is a single and consistent entity, and to analyze cancer metabolism in the 
context of the tissue of origin, the (epi)genetics of the individual tumors, signaling aberrations, cancer cell heterogeneity 
(including cancer associate cells), and the associated microenvironment. Thus, metabolic drugs require that we move from a 
general standard therapy towards personalized medicine. Given the dramatic variance in tissue and specific metabolism, the 
possibility of a targeted delivery of drugs opens another horizon for metabolism-based therapeutic strategies. 
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Figure Legends: 
 
Figure 1: Breast cancer metabolism. A) Metabolism of triple-negative breast cancer. B) Metabolism of estrogen-positive breast 
cancer. Yellow arrows depict the main fluxes within central metabolism and the dashed lines indicate a down-regulation of the 
according metabolic pathway. The reportedly altered enzyme activities are described on the right of each panel, where bold 
names indicate an up-regulation and condensed names a down-regulation of the according enzymes. Abbreviations: G6P: 
glucose-6-phosphate, F6P: fructose-6-phosphate, F26BP: fructose-2,6-bisphosphate, F16BP: fructose-1,6-bisphosphate, GAP: 
glyceraldehyde-phosphate, DHAP: dihydroxyacetone-phosphate, 3PG: 3-phosphoglycerate, PEP: phosphoenol-pyruvate, 6PG: 6-
phosphogluconate, R5P: ribose-5-phosphate, Pyr: pyruvate, AcCoA: acetyl-CoA, FA: fatty acids, αKG: α-ketoglutarate, OAA: 
oxaloacetate. 
 
Figure 2: Liver cancer metabolism. A) Metabolism of normal hepatocytes. B) Metabolism of liver cancer. Yellow arrows depict 
the main fluxes within central metabolism and the dashed lines indicate a down-regulation of the according metabolic pathway. 
The reportedly altered enzyme activities are described on the right of each panel, where bold names indicate an up-regulation 
and condensed names a down-regulation of the according enzymes. Abbreviations: G6P: glucose-6-phosphate, F6P: fructose-6-
phosphate, F26BP: fructose-2,6-bisphosphate, F16BP: fructose-1,6-bisphosphate, GAP: glyceraldehyde-phosphate, DHAP: 
dihydroxyacetone-phosphate, 3PG: 3-phosphoglycerate, PEP: phosphoenol-pyruvate, 6PG: 6-phosphogluconate, R5P: ribose-5-
phosphate, Pyr: pyruvate, AcCoA: acetyl-CoA, FA: fatty acids, αKG: α-ketoglutarate, OAA: oxaloacetate. 
 
Figure 3: Prostate metabolism at different stages of carcinogenesis. A) Metabolism of healthy prostate fibroblasts. B) Early 
prostate cancer metabolism C) Late stage prostate cancer metabolism. Yellow arrows depict the main fluxes within central 
metabolism and the dashed lines indicate a down-regulation of the according metabolic pathway. The reportedly altered enzyme 
activities are described on the right of each panel, where bold names indicate an up-regulation and condensed names a down-
regulation of the according enzymes. Abbreviations: G6P: glucose-6-phosphate, F6P: fructose-6-phosphate, F26BP: fructose-2,6-
bisphosphate, F16BP: fructose-1,6-bisphosphate, GAP: glyceraldehyde-phosphate, DHAP: dihydroxyacetone-phosphate, 3PG: 3-
phosphoglycerate, PEP: phosphoenol-pyruvate, 6PG: 6-phosphogluconate, R5P: ribose-5-phosphate, Pyr: pyruvate, AcCoA: 
acetyl-CoA, FA: fatty acids, αKG: α-ketoglutarate, OAA: oxaloacetate. 
 
Table Legend: 
Table 1: Metabolic targets in tumor therapy. Updated and extended summary based on Galluzzi et al. [6] Abbreviations: PFKFB3: 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3, PFKFB4: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4, 
PKM2: pyruvate kinase muscle isozyme 2, HK: hexokinase, PGAM: phosphoglycerate mutase family, G6Pase: Glucose 6-
phosphatase, PEPCK: phosphoenolpyruvate carboxykinase, CK: choline kinase, ACLY: ATP citrate lyase, FASN: fatty acid synthase, 
MGLL: monoacylglycerol lipase, CPT1C: carnitine palmitoyltransferase-1C, HMGCR: 3-Hydroxy-3-methylglutaryl-CoA reductase, 
PDK1: pyruvate dehydrogenase kinase-1, GLS1: glutaminase 1, GDH: Glutamate Dehydrogenase, IDH1/2: isocitrate 
dehydrogenase 1/2, MCT1: monocarboxylate transporter 1, MCT4: monocarboxylate transporter 4, MAE2: malic enzyme 2, 
PhGDH: phosphoglycerate dehydrogenase, ODC: ornithine decarboxylase, DHFR: dihydrofolate reductase, RNR: ribonucleotide 
reductase. 
 
Target  Mode of action Agent Stage of development Indication Ref. 
Gycolysis 
Glucose 
transporters   
Depletion Ritonavir (off-
target inhibitory 
effects on GLUT4) 
 
WZB117  
Preclinical 
 
 
 
Preclinical 
Multiple myeloma 
 
 
 
Lung cancer 
[210, 211] 
 
PFKFB3  Normalization 3PO 
 
PFK158 
Preclinical 
 
Phase I  
Lung, breast leukemic 
tumors 
Advanced malignancies 
[212-214] 
PFKFB4 Normalization RNAi Preclinical Multiple cancer cell lines [215, 216] 
PKM2  Normalization Shikonin 
 
TLN-232 
 
Preclinical  
 
discontinued clinical 
trials  
Various cancers 
 
Metastatic melanoma 
[217-219] 
HK Depletion 2-DG, 3-BP, 
Lonidamine 
 
Methyl jasmonate 
Discontinued clinical 
trials 
 
Preclinical  
Advanced solid tumors 
 
Bladder and breast cancer 
[220] 
PGAM Depletion Preclinical 
compounds 
Preclinical Breast cancer [221] 
MCT4 Depletion RNAi Preclinical Glioblastoma [222] 
Gluconeogenesis 
G6Pase, PEPCK Normalization Dexamethasone Preclinical Liver cancer [80] 
Fatty acid metabolism 
CK  Depletion TCD-717 Approved Phase I  Advanced Solid Tumors [199] 
ACLY  Depletion RNAi, preclinical 
compounds 
Preclinical Various cancers [223-225] 
FASN  Depletion TVB-2640 Phase I  Advanced Solid Tumors [226] 
MGLL Depletion CK37 
JZL184 
Preclinical  Various cancer cells [227, 228] 
CPT1C  Depletion RNAi Preclinical  Lung tumor [229] 
HMGCR Depletion Statins Approved  Solid tumors [230] 
TCA cycle and mitochondrial metabolism 
PDK1 Normalization DCA Phase II  Glioblastoma; melanoma; 
Non-small cell lung cancer 
[231, 232] 
Complex I Depletion Metformin Approved (not for 
cancer) 
Metformin treatment 
improves outcomes in 
cancer patients  
[233-235] 
GLS1 Normalization RNAi, preclinical 
compounds 
CB-839 
Preclinical 
 
Phase I  
 
 
Advanced hematologic 
malignancies and 
Solid tumors 
 
 
 
 
[236, 237] 
GDH Depletion RNAi, preclinical 
compounds 
EGCG 
Preclinical Glioblastoma cells [238-240] 
Mutant IDH1/2  Normalization RNAi, preclinical 
compounds 
 
AG-221 
 
 
AG-120 
Preclinical 
 
 
Phase I 
 
 
Phase I 
Glioma,leukemia 
 
 
Acute myeloid leukemia 
 
Advanced hematologic 
tumor and solid tumors 
 
 
 
 
 
 
[241-245] 
MCT1 Depletion RNAi, preclinical 
compounds (AR‑
C155858,             
AR‑117977), 
 
AZD3965 inhibitor 
 
 
 
 
 
Phase I  
 
 
 
 
 
Advanced cancers 
 
 
 
 
 
[246, 247] 
MAE2 Normalization RNAi Preclinical Leukemia; Solid tumors [248, 249] 
Amino acid metabolism  
Asparagine  Depletion L-asparaginase Approved  Leukemia [194] 
PhGDH Depletion RNAi Preclinical Melanoma; Breast cancer [42, 43] 
Arginine Depletion Arginine 
deaminase 
conjugated to PEG 
Phase II HCC (Phase II/III); 
Melanoma (Phase I/II) 
[250] 
ODC Depletion DMFO Phase II Neuroblastoma [251] 
Nucleic acid synthesis 
DHFR Depletion Methotrexate Approved Various types of cancer [252-
254] 
Nucleoside 
analogs 
Depletion 5-FU Approved  Solid cancer [255] 
RNR Depletion Gemcitabine Approved Pancreatic cancer [256] 
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 Figure 1: Breast cancer metabolism. A) Metabolism of triple-negative breast cancer. B) Metabolism of estrogen-positive breast 
cancer. Yellow arrows depict the main fluxes within central metabolism and the dashed lines indicate a down-regulation of the 
according metabolic pathway. The reportedly altered enzyme activities are described on the right of each panel, where bold 
names indicate an up-regulation and condensed names a down-regulation of the according enzymes. Abbreviations: G6P: 
glucose-6-phosphate, F6P: fructose-6-phosphate, F26BP: fructose-2,6-bisphosphate, F16BP: fructose-1,6-bisphosphate, GAP: 
glyceraldehyde-phosphate, DHAP: dihydroxyacetone-phosphate, 3PG: 3-phosphoglycerate, PEP: phosphoenol-pyruvate, 6PG: 6-
phosphogluconate, R5P: ribose-5-phosphate, Pyr: pyruvate, AcCoA: acetyl-CoA, FA: fatty acids, αKG: α-ketoglutarate, OAA: 
oxaloacetate. 
 
 
 
 
 Figure 2: Liver cancer metabolism. A) Metabolism of normal hepatocytes. B) Metabolism of liver cancer. Yellow arrows depict 
the main fluxes within central metabolism and the dashed lines indicate a down-regulation of the according metabolic pathway. 
The reportedly altered enzyme activities are described on the right of each panel, where bold names indicate an up-regulation 
and condensed names a down-regulation of the according enzymes. Abbreviations: G6P: glucose-6-phosphate, F6P: fructose-6-
phosphate, F26BP: fructose-2,6-bisphosphate, F16BP: fructose-1,6-bisphosphate, GAP: glyceraldehyde-phosphate, DHAP: 
dihydroxyacetone-phosphate, 3PG: 3-phosphoglycerate, PEP: phosphoenol-pyruvate, 6PG: 6-phosphogluconate, R5P: ribose-5-
phosphate, Pyr: pyruvate, AcCoA: acetyl-CoA, FA: fatty acids, αKG: α-ketoglutarate, OAA: oxaloacetate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: Prostate metabolism at different stages of carcinogenesis. A) Metabolism of healthy prostate fibroblasts. B) Early 
prostate cancer metabolism C) Late stage prostate cancer metabolism. Yellow arrows depict the main fluxes within central 
metabolism and the dashed lines indicate a down-regulation of the according metabolic pathway. The reportedly altered enzyme 
activities are described on the right of each panel, where bold names indicate an up-regulation and condensed names a down-
regulation of the according enzymes. Abbreviations: G6P: glucose-6-phosphate, F6P: fructose-6-phosphate, F26BP: fructose-2,6-
bisphosphate, F16BP: fructose-1,6-bisphosphate, GAP: glyceraldehyde-phosphate, DHAP: dihydroxyacetone-phosphate, 3PG: 3-
phosphoglycerate, PEP: phosphoenol-pyruvate, 6PG: 6-phosphogluconate, R5P: ribose-5-phosphate, Pyr: pyruvate, AcCoA: 
acetyl-CoA, FA: fatty acids, αKG: α-ketoglutarate, OAA: oxaloacetate. 
 
